In vitro effects of retinoids on the proliferation and differentiation features of Epstein-Barr virus-immortalized B lymphocytes

Leukemia and Lymphoma

Volumn 29, Issue 3-4, 1998, Pages 269-281

  Dolcetti, Riccardo ^a   Zancai, Paola ^a   Cariati, Roberta ^a   Boiocchi, Mauro ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

B lymphocytes; Epstein Barr virus; Malignant lymphomas; Retinoids

Indexed keywords

ALITRETINOIN; ISOTRETINOIN; PROTEIN P27; RETINOIC ACID; RETINOID;

ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL IMMORTALIZATION; EPSTEIN BARR VIRUS; GROWTH INHIBITION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

EID: 0031843948     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809068564     Document Type: Article

References (44)

1. De Luca, L. M. (1993). Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J., 5, 2924-2933.
2. Mangelsdorf, D. J., Kliewer, S. A., Kakizuka, A., Umesono, K. and Evans, R. M. (1995). The retinoid receptors. In: M., Sporn, A. B., Roberts and D. S. Goodman (eds.). The Retinoids. Biology, chemistry and medicine. (Raven Press, New York). pp. 319-349.
3. Allegretto, E. A., McClurg, M. R., Lazarchik, S. B., Clemm, D. L., Kerner, S. A., Elgort, M. G., Bohem, M. F., White, S. K., Pike, J. W. and Heyman, R. A. (1993). Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J. Biol. Chem., 268, 26625-26633.
4. Mori, S. (1922). The changes in the para-ocular glands which follow the administration of diets low in fat-soluble A: with notes on the effect of the same diets on the salivary glands and the mucosa of the larynx and trachea. Bull. Johns Hopkins Hosp., 33, 357-359.
5. Wolbach, S. B. and Howe, P. R. (1925). Tissue changes following deprivation of fat-soluble A-vitamin. J. Exp. Med., 42, 753-778.
6. Kark, J. D., Smith, A. H., Switzer, B. R. and Hames, C. G. (1981). Serum vitamin A (retinol) and cancer incidence in Evans County, Georgia. J. Natl. Cancer Inst., 66, 7-16.
7. Moon, R. C., Mehta, R. G. and Rao, K. V. N. (1994). Retinoids and cancer in experimental animals, in M. B., Sporn, A. B., Roberts, D. S. Goodman, (eds.) The Retinoids. Biology, chemistry and medicine. (Raven Press, New York), pp. 573-596.
8. Smith, M. A., Parkinson, D. R., Cheson, B. D. and Friedman, M. A. (1992). Retinoids in cancer therapy. J. Clin. Oncol., 10, 839-864.
9. Warrell, R. P., Jr. (1994). Applications for retinoids in cancer therapy. Semin. Hematol., 31, 1-13.
10. Tallman, M. S. (1994). All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies. Semin. Hematol., 31, 38-48.
11. Miller, W. H., Jr. (1996). Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features. Cancer Invest., 14, 142-150.
12. Abb, J. and Deinhardt, F. (1980). Effects of retinoid acid on the human lymphocyte response to mitogens. Exp. Cell Biol., 48, 169-179.
13. 2+ currents and cell proliferation in a B lymphocyte cell line. J. Cell. Physiol., 135, 317-323.
14. Buck, J., Dannecker, L., Viswanathan, K., Cohen, S. L., Chait, B. T. and Hämmerling, U. (1990). Retinol is essential for growth of activated human B cells. J. Exp. Med., 171, 1613-1624.
15. Buck, J., Myc, A., Garbe, A. and Cathomas, G. (1991). Differences in the action and metabolism between retinol and retinoic acid in B lymphocytes. J. Cell. Biol., 115, 851-859.
16. Blomhoff, H. K., Smeland, E. B., Erikstein, B., Rasmussen, A. M., Skrede, B., Skjønsberg, C. and Blomhoff, R. (1992). Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B-cells. J. Biol. Chem., 25, 23988-23992.
17. Fahlman, C., Jacobsen, S. E., Smeland, E. B., Lømo, J., Næss, C. E., Funderud, S. and Blomhoff, H. K. (1995). All-trans- and 9-cis-retinoic acid inhibit growth of normal human and murine B cell precursors. J. Immunol., 155, 58-65.
18. Nilsson, K., Giovannella, B. C., Stehlin, J. S. and Klein, G. (1977). Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int. J. Cancer, 19, 337-
19. Calender, A., Billaud, M., Aubry, J., Banchereau, J., Vuillaume, M. and Lenoir, G. (1987). EBV induces expression of B cell activation markers on in vitro infection of EBV negative B lymphoma cells. Proc. Natl. Acad. Sci. U.S.A., 84, 8060-8064.
20. Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. and Kieff, E. (1990). Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol., 64, 2309-2318.
21. Cohen, J. I., Wang, F. and Kieff, E. (1991). Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J. Virol., 65, 2545-2554.
22. Kaye, K. M., Isuzmi, K. M. and Kieff, E. (1993). Epstein-Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation. Proc. Natl. Acad. Sci. U.S.A., 90, 9150-9154.
23. Nalesnik, M. A., Jaffe, R., Starzi, T. E., Demetris, A. J., Porter, K., Burnham, J. A., Makowka, L., Ho, M. and Locker, J. (1988). The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol., 133, 173-192.
24. Young, L., Alfieri, C., Hennessy, K., Evans, H., O'Hara, C., Anderson, K. C., Ritz, J., Shapiro, R. S., Rickinson, A., Kieff, E. and Cohen, J. I. (1989). Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med., 321, 1080-1085.
25. Chadburn, A., Cesarman, E. and Knowles, D. M. (1997). Molecular pathology of posttransplantation lymphoproliferative disorders. Semin. Diagn. Pathol., 14, 15-26.
26. Pomponi, F., Cariati, R., Zancai, P., De Paoli, P., Rizzo, S., Tedeschi, R. M., Pivetta, B., De Vita, S., Boiocchi, M. and Dolcetti, R. (1996). Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood, 88, 3147-3159.
27. Adamson, P. C. (1994). Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia. Semin. Hematol., 31, Suppl. 5, 14-17.
28. Giannini, F., Maestro, R., Vukosavljevic, T., Pomponi, F. and Boiocchi, M. (1997). All-trans, 13-cis and 9-cis retinoic acid induce a fully reversible growth inhibition in HNSCC cell lines: implications for in vivo retinoic acid use. Int. J. Cancer, 70, 194-200.
29. Bollag, W. and Holdener, E. E. (1992). Retinoids in cancer prevention and therapy. Ann. Oncol., 3, 513-526.
30. Schroder, E. W., Rapaport, E., Kabcenell, A. K. and Black, P. H. (1982). Growth inhibitory and stimulatory effects of retinoic acid on murine 3T3 cells. Proc. Natl. Acad. Sci. U.S.A., 79, 1549-1552.
31. Marth, C., Böck, G. and Daxenbichler, G. (1985). Effect of 4-hydroxyphenyl-retinamide and retinoid acid on proliferation and cell cycle of cultured human breast cancer cells. J. Natl. Cancer Inst., 75, 871-875.
32. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78, 59-66.
33. 1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78, 67-74.
34. Roberts, J. M., Koff, A., Polyak, K., Firpo, E., Collins, S., Ohtsubo, M. and Massagué, J. (1994). Cyclins, Cdks and cyclin kinase inhibitors. Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor Laboratory Press, Vol. 59, pp 31-38.
35. Hengst, L., Dulic, V., Slingerland, J., Lees, E. and Reed, S. I. (1994). A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. U.S.A., 91, 5291-5295.
36. Kato, J., Matsuoka, M., Polyak, K., Massagué, J. and Sherr, C. (1994). Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 Kip1) of cyclin-dependent kinase 4 activation. Cell, 79, 487-496.
37. Cutrona, G., Ulivi, M., Fais, F., Roncella, S. and Ferrarini, M. (1995). Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts. J. Exp. Med., 181, 699-711.
38. Wang, W. and Ballow, M. (1993). The effects of retinoic acid on in vitro immunoglobulin synthesis by cord blood and adult peripheral blood mononuclear cells. Cell. Immunol., 148, 291-300.
39. Israel, H., Odziemiec, C. and Ballow, M. (1991). The effects of retinoic acid on immunoglobulin synthesis by human cord blood mononuclear cells. Clin. Immunol. Immunopathol., 59, 417-425.
40. Sherr, E., Adelman, D. C, Saxon, A., Gilly, M., Wall, R. and Sidell, N. (1988). Retinoid acid induces the differentiation of B-cell hybridomas from patients with common variable immunodeficency. J. Exp. Med., 168, 55-71.
41. Wendel-Hansen, V., Rosén, A. and Klein, G. (1987). EBV-transformed lymphoblastoid cell lines down-regulate EBNA in parallel with secretory differentiation. Int. J. Cancer, 39, 404-408.
42. Delecluse, H-J., Kremmer, E., Rouault, J-P., Cour, C., Bornkamm, G. and Berger, F. (1995). The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am. J. Pathol., 146, 1113-1120.
43. Picchio, G. R., Kobayashi, R., Kirven, M., Baird, S. M., Kipps, T. J. and Mosier, D. E. ( 1992). Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in scid mice receiving human peripheral blood leukocyte grafts. Cancer Res., 52, 2468-2477.
44. Rochford, R., Hobbs, M. V., Gamier, J-L., Cooper, N. R. and Cannon, M. J. (1993). Plasmacytoid differentiation of Epstein-Barr virus-transformed B-cells in vivo is associated with reduced expression of viral latent genes. Proc. Natl. Acad. Sci. U.S.A., 90, 352-356.